About Ligand Pharmaceuticals Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.ligand.com/
Frequently Asked Questions
What is the 52-week range for LGND?
The 52-week high is $326.63 and the 52-week low is $175.56.
What is the P/E ratio for LGND?
The Price to Earnings (P/E) ratio is 30.84.
What is the dividend yield for LGND?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 20.06%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 67.88%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.66.
Analyst Recommendation Trends
Wall Street analyst consensus for LGND over the last few months:
Latest LGND News
Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell?
Why the AvenCell financing matters for Ligand Pharmaceuticals Ligand Pharmaceuticals (LGND) has agreed to provide up to $47 million in funding to AvenCell Therapeutics, tying most of the capital to clinical milestones in AvenCell’s CAR-T therapy programs. The agreement extends Ligand’s royalty-focused approach, giving the business potential future royalty rights on AvenCell’s existing CAR-T pipeline and any later programs that emerge from the partnership. Recent trading has been strong for...
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal
Ligand Pharmaceuticals has delivered a very strong run in recent years, and the question now is whether the cash the business can generate is enough to support where the stock trades today. With a Discounted Cash Flow (DCF) view available, the focus naturally turns to how the current price lines up with the cash flows investors expect the company to produce over time. Over the past 3 years, Ligand Pharmaceuticals has returned about 430.8%, which puts a lot of weight on whether the cash flow...
Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook?
Ligand Pharmaceuticals recently entered a US$47 million financing agreement with AvenCell Therapeutics, including up to US$6 million in Series C funding and as much as US$41 million tied to clinical milestones for AvenCell’s CAR-T therapy programs. The deal deepens Ligand’s royalty-focused model by adding potential royalty streams on AvenCell’s current and future pipeline, further broadening its portfolio of over 200 partnered assets following the XOMA Royalty acquisition. We’ll now examine...
Ligand Pharmaceuticals (NASDAQ:LGND) Flashes Strong Trend and High-Growth Momentum Despite Setup Caution
LGND stock shows strong Minervini trend, high-growth fundamentals, and 93 RS; setup is less ideal, so still wait for a tighter base before entry today.
Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is building a business model that differs from that of many drug developers. Rather than relying on internally operated drug development programs, the company funds third-party programs and acquires royalty interests in exchange for economic rights in those assets. That model allows it to generate royalties and other income when the […]
IBM upgrade, SpaceX initiation among today's top calls on Wall Street
IBM upgrade, SpaceX initiation among today's top calls on Wall Street
Barclays Initiates Coverage On Ligand Pharmaceuticals with Overweight Rating, Announces Price Target of $345
Barclays analyst Glen Santangelo initiates coverage on Ligand Pharmaceuticals (NASDAQ:LGND) with a Overweight rating and announces Price Target of $345.
HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $358 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and maintains $358 price target.
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment will help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the t
Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $390 to $397.
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
DEL MAR, Calif., September 22, 2026--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA).
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose's Board of Directors.
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.’s (“Santen”) Ryj
Sydnexis Signs $23M Agreement With Ligand Pharmaceuticals To Sell Its Royalty Rights Associated With Net Sales Of Ryjunea In EMEA
Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated
Here’s How Much You Would Have Made Owning Ligand Pharmaceuticals Stock In The Last 5 Years
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 5 years by 15.5% on an annualized basis producing an average annual return of 27.11%. Currently, Ligand Pharmaceuticals has a market
Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold
Ligand Pharmaceuticals is rated a Hold, preferring entry after a pullback, given valuation risks and concentration concerns. Click for more on LGND.
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book
On August 6, Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results showing royalty revenue up 32% year over year, just weeks after the company closed its acquisition of XOMA Royalty. Total revenue reached $63.7 million for the quarter, up from $47.6 million a year earlier, and Ligand raised the low end of its full-year adjusted earnings […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-22 | Zimmermann Martine | -115 | $298.5 | $34,328 |
| 2026-09-10 | Zimmermann Martine | -1,200 | $285 | $342,000 |
| 2026-09-03 | Reardon Andrew | -400 | $288.9792 | $115,592 |
| 2026-09-03 | Reardon Andrew | -385 | $287.5253 | $110,697 |
| 2026-09-03 | Reardon Andrew | -2,115 | $286.3589 | $605,649 |
| 2026-09-03 | Reardon Andrew | -1,800 | $285.1671 | $513,301 |
| 2026-09-03 | Reardon Andrew | -300 | $283.9854 | $85,196 |
| 2026-08-12 | Espinoza Octavio | -2,074 | - | - |
| 2026-08-12 | Espinoza Octavio | -3,348 | - | - |
| 2026-08-12 | Espinoza Octavio | -16,179 | - | - |
| 2026-08-12 | Espinoza Octavio | -7,171 | - | - |
| 2026-08-12 | Espinoza Octavio | -2,869 | - | - |
| 2026-08-12 | Espinoza Octavio | -31,641 | $292.065 | $9,241,229 |
| 2026-08-12 | Espinoza Octavio | +3,348 | $68.74 | $230,142 |
| 2026-08-12 | Espinoza Octavio | +7,171 | $57.22 | $410,325 |
| 2026-08-12 | Espinoza Octavio | +2,869 | $55.75 | $159,947 |
| 2026-08-12 | Espinoza Octavio | +2,074 | $70.04 | $145,263 |
| 2026-08-12 | Espinoza Octavio | +16,179 | $52.84 | $854,898 |
| 2026-08-12 | Haas Jason | -6,138 | - | - |
| 2026-08-12 | Haas Jason | -7,138 | $292.8078 | $2,090,062 |
| 2026-08-12 | Haas Jason | +6,138 | $51.56 | $316,475 |
| 2026-08-03 | Reardon Andrew | -5,000 | - | - |
| 2026-08-03 | Reardon Andrew | -409 | $292.8191 | $119,763 |
| 2026-08-03 | Reardon Andrew | -991 | $291.7119 | $289,086 |
| 2026-08-03 | Reardon Andrew | -200 | $290.6 | $58,120 |
| 2026-08-03 | Reardon Andrew | -503 | $289.8022 | $145,771 |
| 2026-08-03 | Reardon Andrew | -356 | $288.7496 | $102,795 |
| 2026-08-03 | Reardon Andrew | -1,214 | $287.7731 | $349,357 |
| 2026-08-03 | Reardon Andrew | -1,032 | $286.7968 | $295,974 |
| 2026-08-03 | Reardon Andrew | -157 | $285.7357 | $44,861 |
| 2026-08-03 | Reardon Andrew | -33 | $284.553 | $9,390 |
| 2026-08-03 | Reardon Andrew | -105 | $284.1375 | $29,834 |
| 2026-08-03 | Reardon Andrew | +5,000 | $52.27 | $261,350 |
| 2026-07-01 | Reardon Andrew | -5,000 | - | - |
| 2026-07-01 | Reardon Andrew | -600 | $317.1517 | $190,291 |
| 2026-07-01 | Reardon Andrew | -900 | $315.7775 | $284,200 |
| 2026-07-01 | Reardon Andrew | -100 | $314.5788 | $31,458 |
| 2026-07-01 | Reardon Andrew | -700 | $313.4574 | $219,420 |
| 2026-07-01 | Reardon Andrew | -1,081 | $312.2784 | $337,573 |
| 2026-07-01 | Reardon Andrew | -1,119 | $311.72 | $348,815 |
| 2026-07-01 | Reardon Andrew | -104 | $310.2023 | $32,261 |
| 2026-07-01 | Reardon Andrew | -396 | $308.9886 | $122,359 |
| 2026-07-01 | Reardon Andrew | +5,000 | $52.27 | $261,350 |
| 2026-06-30 | Reardon Andrew | +132 | $160.7095 | $21,214 |
| 2026-06-30 | Espinoza Octavio | +17 | $160.7095 | $2,732 |
| 2026-06-30 | Davis Todd C | +132 | $160.7095 | $21,214 |
| 2026-06-16 | Sabba Stephen L | -2,145 | - | - |
| 2026-06-16 | Sabba Stephen L | -2,145 | $254 | $544,830 |
| 2026-06-16 | Sabba Stephen L | +2,145 | $66.13 | $141,849 |
| 2026-06-12 | Haas Jason | -1,000 | - | - |
| 2026-06-12 | Haas Jason | -3,000 | - | - |
| 2026-06-12 | Haas Jason | -3,461 | $256.0781 | $886,286 |
| 2026-06-12 | Haas Jason | -3,000 | $255.0113 | $765,034 |
| 2026-06-12 | Haas Jason | +1,000 | $51.56 | $51,560 |
| 2026-06-12 | Haas Jason | +3,000 | $51.56 | $154,680 |
| 2026-06-11 | Aryeh Jason | -4,500 | $250 | $1,125,000 |
| 2026-06-10 | Aryeh Jason | -500 | $250 | $125,000 |
| 2026-06-10 | LAMATTINA JOHN L | -3,405 | $251.6158 | $856,752 |
| 2026-06-10 | LAMATTINA JOHN L | -697 | $249.5326 | $173,924 |
| 2026-06-10 | LAMATTINA JOHN L | -232 | $248.1111 | $57,562 |
| 2026-06-10 | LAMATTINA JOHN L | -257 | $247.2237 | $63,536 |
| 2026-06-05 | Aryeh Jason | +2,938 | - | - |
| 2026-06-05 | Aryeh Jason | +836 | - | - |
| 2026-06-05 | Zimmermann Martine | +2,938 | - | - |
| 2026-06-05 | Zimmermann Martine | -182 | $237 | $43,134 |
| 2026-06-05 | Zimmermann Martine | +836 | - | - |
| 2026-06-05 | Haas Jason | +2,938 | - | - |
| 2026-06-05 | Haas Jason | +836 | - | - |
| 2026-06-05 | Gray Nancy Ryan | +2,938 | - | - |
| 2026-06-05 | Gray Nancy Ryan | +836 | - | - |
| 2026-06-05 | Sabba Stephen L | +2,938 | - | - |
| 2026-06-05 | Sabba Stephen L | +836 | - | - |
| 2026-06-05 | KOZARICH JOHN W | +2,938 | - | - |
| 2026-06-05 | KOZARICH JOHN W | +836 | - | - |
| 2026-06-05 | LAMATTINA JOHN L | +2,938 | - | - |
| 2026-06-05 | LAMATTINA JOHN L | +836 | - | - |
| 2026-06-01 | Reardon Andrew | -5,000 | - | - |
| 2026-06-01 | Reardon Andrew | -200 | $230.41 | $46,082 |
| 2026-06-01 | Reardon Andrew | -1,216 | $229.4676 | $279,033 |
| 2026-06-01 | Reardon Andrew | -584 | $228.5738 | $133,487 |
| 2026-06-01 | Reardon Andrew | -400 | $226.7794 | $90,712 |
| 2026-06-01 | Reardon Andrew | -1,432 | $225.9672 | $323,585 |
| 2026-06-01 | Reardon Andrew | -677 | $225.1983 | $152,459 |
| 2026-06-01 | Reardon Andrew | -491 | $223.9467 | $109,958 |
| 2026-06-01 | Reardon Andrew | +5,000 | $52.27 | $261,350 |
| 2026-05-27 | Espinoza Octavio | -764 | - | - |
| 2026-05-27 | Espinoza Octavio | -972 | - | - |
| 2026-05-27 | Espinoza Octavio | +972 | $52.84 | $51,360 |
| 2026-05-27 | Espinoza Octavio | +764 | $63.62 | $48,606 |
| 2026-05-13 | KOZARICH JOHN W | -1,575 | - | - |
| 2026-05-13 | KOZARICH JOHN W | -1,575 | $223.5 | $352,013 |
| 2026-05-13 | KOZARICH JOHN W | +1,575 | $69.51 | $109,478 |
| 2026-05-12 | KOZARICH JOHN W | -459 | - | - |
| 2026-05-12 | KOZARICH JOHN W | -459 | $224 | $102,816 |
| 2026-05-12 | KOZARICH JOHN W | +459 | $69.51 | $31,905 |
| 2026-05-01 | KOZARICH JOHN W | -116 | $234.0853 | $27,154 |
| 2026-05-01 | KOZARICH JOHN W | -105 | $232.5704 | $24,420 |
| 2026-05-01 | KOZARICH JOHN W | -165 | $231.8671 | $38,258 |
| 2026-05-01 | KOZARICH JOHN W | -1 | $229.87 | $230 |
| 2026-05-01 | KOZARICH JOHN W | -80 | $227.3675 | $18,189 |
| 2026-05-01 | Reardon Andrew | -5,000 | - | - |
| 2026-05-01 | Reardon Andrew | -800 | $234.0177 | $187,214 |
| 2026-05-01 | Reardon Andrew | -1,420 | $232.922 | $330,749 |
| 2026-05-01 | Reardon Andrew | -780 | $232.0399 | $180,991 |
| 2026-05-01 | Reardon Andrew | -370 | $230.8692 | $85,422 |
| 2026-05-01 | Reardon Andrew | -98 | $229.7086 | $22,511 |
| 2026-05-01 | Reardon Andrew | -932 | $228.7537 | $213,198 |
| 2026-05-01 | Reardon Andrew | -600 | $227.4493 | $136,470 |
| 2026-05-01 | Reardon Andrew | +5,000 | $52.27 | $261,350 |
| 2026-04-01 | Reardon Andrew | -5,000 | - | - |
| 2026-04-01 | Reardon Andrew | -337 | $204.5026 | $68,917 |
| 2026-04-01 | Reardon Andrew | -963 | $203.2218 | $195,703 |
| 2026-04-01 | Reardon Andrew | -700 | $201.8971 | $141,328 |
| 2026-04-01 | Reardon Andrew | -1,238 | $200.9429 | $248,767 |
| 2026-04-01 | Reardon Andrew | -1,302 | $199.7221 | $260,038 |
| 2026-04-01 | Reardon Andrew | -460 | $198.8493 | $91,471 |
| 2026-04-01 | Reardon Andrew | +5,000 | $52.27 | $261,350 |
| 2026-04-01 | KOZARICH JOHN W | -159 | $204.2627 | $32,478 |
| 2026-04-01 | KOZARICH JOHN W | -43 | $202.9122 | $8,725 |
| 2026-04-01 | KOZARICH JOHN W | -79 | $202.4223 | $15,991 |
| 2026-04-01 | KOZARICH JOHN W | -40 | $201.235 | $8,049 |
| 2026-04-01 | KOZARICH JOHN W | -146 | $199.9749 | $29,196 |
| 2026-03-23 | Sabba Stephen L | -1,000 | $207.8727 | $207,873 |
| 2026-03-11 | Espinoza Octavio | -2,405 | - | - |
| 2026-03-11 | Espinoza Octavio | -3,057 | $225 | $687,825 |
| 2026-03-11 | Espinoza Octavio | +2,405 | $92.65 | $222,823 |
| 2026-03-06 | LAMATTINA JOHN L | -2,161 | - | - |
| 2026-03-06 | LAMATTINA JOHN L | -2,161 | $200.76 | $433,842 |
| 2026-03-06 | LAMATTINA JOHN L | +2,161 | $114.15 | $246,678 |
| 2026-03-04 | Reardon Andrew | -5,000 | - | - |
| 2026-03-04 | Reardon Andrew | -1,142 | $208.8724 | $238,532 |
| 2026-03-04 | Reardon Andrew | -1,446 | $208.1183 | $300,939 |
| 2026-03-04 | Reardon Andrew | -612 | $207.0089 | $126,689 |
| 2026-03-04 | Reardon Andrew | -340 | $206.367 | $70,165 |
| 2026-03-04 | Reardon Andrew | -460 | $205.178 | $94,382 |
| 2026-03-04 | Reardon Andrew | -200 | $204.17 | $40,834 |
| 2026-03-04 | Reardon Andrew | -300 | $201.7 | $60,510 |
| 2026-03-04 | Reardon Andrew | -93 | $200.6225 | $18,658 |
| 2026-03-04 | Reardon Andrew | -207 | $199.956 | $41,391 |
| 2026-03-04 | Reardon Andrew | -100 | $199.005 | $19,901 |
| 2026-03-04 | Reardon Andrew | -100 | $197.6954 | $19,770 |
| 2026-03-04 | Reardon Andrew | +5,000 | $52.27 | $261,350 |
| 2026-03-04 | Espinoza Octavio | -466 | - | - |
| 2026-03-04 | Espinoza Octavio | -1,607 | - | - |
| 2026-03-04 | Espinoza Octavio | -3,413 | $208.796 | $712,621 |
| 2026-03-04 | Espinoza Octavio | -2,457 | $207.9052 | $510,823 |
| 2026-03-04 | Espinoza Octavio | -1,588 | $206.8904 | $328,542 |
| 2026-03-04 | Espinoza Octavio | -1,457 | $205.7937 | $299,841 |
| 2026-03-04 | Espinoza Octavio | -743 | $204.7449 | $152,125 |
| 2026-03-04 | Espinoza Octavio | -668 | $203.6287 | $136,024 |
| 2026-03-04 | Espinoza Octavio | -697 | $202.7873 | $141,343 |
| 2026-03-04 | Espinoza Octavio | -950 | $201.7266 | $191,640 |
| 2026-03-04 | Espinoza Octavio | -698 | $201.0939 | $140,364 |
| 2026-03-04 | Espinoza Octavio | -53 | $200.0777 | $10,604 |
| 2026-03-04 | Espinoza Octavio | -699 | $198.7052 | $138,895 |
| 2026-03-04 | Espinoza Octavio | +466 | $80.72 | $37,616 |
| 2026-03-04 | Espinoza Octavio | +1,607 | $58.49 | $93,993 |
| 2026-03-03 | Sabba Stephen L | -2,034 | - | - |
| 2026-03-03 | Sabba Stephen L | -2,034 | $201.5 | $409,851 |
| 2026-03-03 | Sabba Stephen L | +2,034 | $69.51 | $141,383 |
| 2026-03-02 | Reardon Andrew | +21,525 | - | - |
| 2026-03-02 | Reardon Andrew | +4,513 | - | - |
| 2026-03-02 | Espinoza Octavio | +23,527 | - | - |
| 2026-03-02 | Espinoza Octavio | +4,933 | - | - |
| 2026-03-02 | Davis Todd C | +50,058 | - | - |
| 2026-03-02 | Davis Todd C | +10,495 | - | - |
| 2026-03-02 | KOZARICH JOHN W | -42 | $203.57 | $8,550 |
| 2026-03-02 | KOZARICH JOHN W | -50 | $202.5388 | $10,127 |
| 2026-03-02 | KOZARICH JOHN W | -83 | $201.6472 | $16,737 |
| 2026-03-02 | KOZARICH JOHN W | -41 | $200.404 | $8,217 |
| 2026-03-02 | KOZARICH JOHN W | -204 | $199.6894 | $40,737 |
| 2026-03-02 | KOZARICH JOHN W | -47 | $197.1397 | $9,266 |
| 2026-02-15 | Reardon Andrew | -992 | $183.83 | $182,359 |
| 2026-02-15 | Reardon Andrew | -801 | $183.83 | $147,248 |
| 2026-02-15 | Reardon Andrew | -593 | $183.83 | $109,011 |
| 2026-02-15 | Espinoza Octavio | -1,270 | $183.83 | $233,464 |
| 2026-02-15 | Espinoza Octavio | -1,223 | $183.83 | $224,824 |
| 2026-02-15 | Espinoza Octavio | -1,026 | $183.83 | $188,610 |
| 2026-02-15 | Davis Todd C | -2,805 | $183.83 | $515,643 |
| 2026-02-15 | Davis Todd C | -4,255 | $183.83 | $782,197 |
| 2026-02-15 | Davis Todd C | -2,039 | $183.83 | $374,829 |
| 2026-02-14 | Reardon Andrew | -4,083 | $183.83 | $750,578 |
| 2026-02-14 | Reardon Andrew | +8,810 | - | - |
| 2026-02-14 | Reardon Andrew | -3,211 | $183.83 | $590,278 |
| 2026-02-14 | Reardon Andrew | +6,928 | - | - |
| 2026-02-14 | Espinoza Octavio | -4,483 | $183.83 | $824,110 |
| 2026-02-14 | Espinoza Octavio | +8,810 | - | - |
| 2026-02-14 | Espinoza Octavio | -3,761 | $183.83 | $691,385 |
| 2026-02-14 | Espinoza Octavio | +7,390 | - | - |
| 2026-02-14 | Davis Todd C | -15,600 | $183.83 | $2,867,748 |
| 2026-02-14 | Davis Todd C | +39,644 | - | - |
| 2026-02-14 | Davis Todd C | -8,178 | $183.83 | $1,503,362 |
| 2026-02-14 | Davis Todd C | +20,782 | - | - |
| 2026-02-02 | KOZARICH JOHN W | -23 | $197.195 | $4,535 |
| 2026-02-02 | KOZARICH JOHN W | -381 | $196.3634 | $74,814 |
| 2026-02-02 | KOZARICH JOHN W | -23 | $195.605 | $4,499 |
| 2026-02-02 | KOZARICH JOHN W | -1 | $192.18 | $192 |
| 2026-02-02 | KOZARICH JOHN W | -39 | $191 | $7,449 |
| 2026-01-02 | KOZARICH JOHN W | -46 | $192.395 | $8,850 |
| 2026-01-02 | KOZARICH JOHN W | -207 | $190.2703 | $39,386 |
| 2026-01-02 | KOZARICH JOHN W | -102 | $188.9627 | $19,274 |
| 2026-01-02 | KOZARICH JOHN W | -91 | $187.9536 | $17,104 |
| 2026-01-02 | KOZARICH JOHN W | -21 | $186.59 | $3,918 |
| 2025-12-31 | Espinoza Octavio | +8 | $95.676 | $765 |
| 2025-12-16 | Espinoza Octavio | -181 | - | - |
| 2025-12-16 | Espinoza Octavio | -652 | - | - |
| 2025-12-16 | Espinoza Octavio | -285 | - | - |
| 2025-12-16 | Espinoza Octavio | -69 | - | - |
| 2025-12-16 | Espinoza Octavio | -1,194 | - | - |
| 2025-12-16 | Espinoza Octavio | +181 | $103.42 | $18,719 |
| 2025-12-16 | Espinoza Octavio | +652 | $92.65 | $60,408 |
| 2025-12-16 | Espinoza Octavio | +285 | $63.62 | $18,132 |
| 2025-12-16 | Espinoza Octavio | +69 | $57.22 | $3,948 |
| 2025-12-16 | Espinoza Octavio | +1,194 | $52.84 | $63,091 |
| 2025-12-12 | Espinoza Octavio | -1,804 | $188.31 | $339,711 |
| 2025-12-08 | Aryeh Jason | -2,034 | - | - |
| 2025-12-08 | Aryeh Jason | +2,034 | $69.51 | $141,383 |
| 2025-12-05 | Espinoza Octavio | -1,862 | $184.87 | $344,228 |
| 2025-12-04 | Davis Todd C | -130 | - | - |
| 2025-12-01 | KOZARICH JOHN W | -30 | $200.0153 | $6,000 |
| 2025-12-01 | KOZARICH JOHN W | -23 | $199.215 | $4,582 |
| 2025-12-01 | KOZARICH JOHN W | -92 | $197.7168 | $18,190 |
| 2025-12-01 | KOZARICH JOHN W | -4 | $196.345 | $785 |
| 2025-12-01 | KOZARICH JOHN W | -47 | $195.7987 | $9,203 |
| 2025-12-01 | KOZARICH JOHN W | -179 | $194.7582 | $34,862 |
| 2025-12-01 | KOZARICH JOHN W | -92 | $193.8577 | $17,835 |
| 2025-11-07 | Gray Nancy Ryan | -3,015 | - | - |
| 2025-11-07 | Gray Nancy Ryan | -3,556 | - | - |
| 2025-11-07 | Gray Nancy Ryan | -3,015 | $205.45 | $619,432 |
| 2025-11-07 | Gray Nancy Ryan | +3,015 | $73.57 | $221,814 |
| 2025-11-07 | Gray Nancy Ryan | -3,556 | $205.45 | $730,580 |
| 2025-11-07 | Gray Nancy Ryan | +3,556 | $66.19 | $235,372 |
| 2025-11-07 | LAMATTINA JOHN L | -2,034 | - | - |
| 2025-11-07 | LAMATTINA JOHN L | -2,145 | - | - |
| 2025-11-07 | LAMATTINA JOHN L | -2,034 | $205.45 | $417,885 |
| 2025-11-07 | LAMATTINA JOHN L | +2,034 | $69.51 | $141,383 |
| 2025-11-07 | LAMATTINA JOHN L | -2,145 | $205.45 | $440,690 |
| 2025-11-07 | LAMATTINA JOHN L | +2,145 | $66.13 | $141,849 |
| 2025-11-03 | KOZARICH JOHN W | -127 | $192.3781 | $24,432 |
| 2025-11-03 | KOZARICH JOHN W | -207 | $191.2494 | $39,589 |
| 2025-11-03 | KOZARICH JOHN W | -49 | $190.2579 | $9,323 |
| 2025-11-03 | KOZARICH JOHN W | -84 | $188.9968 | $15,876 |